Background: Several single-nucleotide variants (SNVs) in collagen genes have been reported as predisposing factors for anterior cruciate ligament (ACL) tears. However, the evidence is conflicting and does not support a clear association between genetic variants and risk of ACL ruptures.
An anterior cruciate ligament (ACL) rupture is a common and severe knee injury. 6 The incidence is high among participants in team sports, and female athletes are especially at risk. 1, 8, 14, 20 Studies documenting a familiar predisposition indicate that genetic factors may play a role in the risk profile for ACL rupture. Harner et al 9 studied athletes with bilateral ACL injuries and found an increased incidence of ACL injuries among the relatives of those athletes as compared with the controls. Flynn et al 5 showed that athletes with an ACL rupture have greater than twice the risk of having a first-, second-, or third-degree relative with an ACL injury than do athletes without such injury. When only first-degree relatives were taken into account, the risk was even greater. 5 Others have shown that siblings with bilateral ACL injuries share intrinsic risk factors. 10 Several studies have identified single-nucleotide variants (SNVs) as potential risk factors for ACL injury. In general, an SNV is a DNA sequence difference between individuals, representing a replacement of one nucleotide by another at a specific location in the genome. The effect of the variant depends on where the SNV is situated relative to the gene of interest, and it can vary from no effect to changes in the expression pattern to translation of altered proteins attributed to substitution of the normal amino acids. Up to now, most studies on ACL injuries investigated their association with SNVs localized in candidate genesfor example, genes coding for different musculoskeletal tissue and structural proteins where alteration in composition or levels is assumed to play a role. In ligaments and tendons, collagen constitutes 70% to 80% of the dry weight.
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Ligament weakening or strengthening by alterations in its main components could affect the incidence of ligament ruptures. Examining the association between different SNVs in genes encoding collagen chains and the risk of ACL rupture is therefore of interest, and so far, known SNVs in COL1A1, 23 However, the genetic association studies published so far are case-control studies, where several sources of bias were identified. 12, 15 The participants were athletes from mixed sports and with varying physical activity levels. In 1 study, the cases were professional soccer players, 3 whereas other studies included only recreational athletes. 23, 27 In most studies, the cases with ACL ruptures were patients with surgically diagnosed ACL rupture. 3, 23, 27 The sampling method for cases was specified in 1 study as convenience sampling 23 and in other studies not specified at all. 28, 29 Usually, the sampling method for controls was not described at all. The studies are mainly restricted to Polish and South African populations, 12 and several included men only. [27] [28] [29] A recent ACL study used a genome-wide approach and not a candidate gene approach. The authors screened for an association between ACL injury and several hundred thousand SNVs scattered throughout the entire genome. No SNV was found to be significantly associated with ACL injury at the genome level. The study included 598 cases with ACL injury and 98,744 controls. 17 Our hypothesis was that SNVs localized in genes coding for collagen proteins represent potential risk factors for ACL injury, and the aim of the current prospective cohort study was to assess the association of previously identified candidate SNVs in genes encoding for collagen and the risk of ACL injury in a population of elite female athletes from high-risk team sports. This population is relatively homogeneous with regard to age, fitness level, and athletic performance and has a high frequency of ACL ruptures.
METHODS

Study Participants
The participants were female athletes from team sports playing at the elite level in Norway and Finland. The cohorts were previously described in detail. 18, 22 The Norwegian athletes were team handball and soccer players, expecting to play in the premier league, who were invited to participate in a 
Previous Injury
Before inclusion, previous ACL injuries were registered by interview with the participants.
Genetic Testing
On the basis of previous case-control studies, 3, 4, 21, [23] [24] [25] 28, 29 6 candidate SNVs of 4 collagen genes-COL1A1, COL3A1, COL5A1, and COL12A1-were selected.
DNA Isolation
EDTA whole blood was collected from all 851 participants and stored at 220°C until analyzed. In Norway, genomic DNA was extracted with a MagNA Pure LC DNA Isolation Kit I (catalog 03 003990 001; Roche) on a MagNAPure LC Instrument (Roche). DNA yield and purity were controlled with a Nanodrop 1000 Spectrophotometer (Thermo Scientific) before storage at 4°C and downstream analysis.
In Finland, genomic DNA was extracted from peripheral blood leukocytes via the QIAamp DNA Blood Minikit and by automated BioRobot M48 extraction (Qiagen).
Genotyping
All selected SNVs (COL1A1: rs1800012, rs1107946; COL3A1: rs1800255; COL5A1: rs12722, rs13946; COL12A1: rs970547) were genotyped by polymerase chain reaction with allelic discrimination and predesigned specific TaqMan SNP Genotyping Assays (Life Technologies, Thermo Fisher Scientific), essentially as recommended by the manufacturer. In Norway, analyses were executed on a Viia7 Real-Time PCR Instrument, and in Finland genotyping was performed by the ABI Prism 7900HT Sequence Detection System (both Applied Biosystems, Thermo Fisher). A nontemplate control and longitudinal controls, representing the 3 genotypes for each SNV, were included in each run.
Injury Registration
During the follow-up period, complete ACL injuries were recorded primarily through regular consultations with the participating teams. 18, 19, 22 Injured players were interviewed and detailed descriptions of the injury situations obtained. All complete ACL tears were verified by magnetic resonance imaging or through arthroscopic examination. Only noncontact injuries were included, defined as no direct contact to the involved leg in the injury situation.
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Statistical Analyses
Statistical analyses were performed with R (v 3.3.1; http:// www.R-project.org/). Categorical variables (SNV and allele frequencies and baseline characteristics) were compared with Pearson chi-square tests or Fisher exact tests, as appropriate. Adjusted analyses were performed with a logistic regression model. Adjustments were made on type of sport and country. Means were compared with the Student t test. A P value \.05 was regarded as significant. Each SNV was tested for Hardy-Weinberg equilibrium with the R package SNPassoc. 7 
RESULTS
The present study included a final sample of 851 participants, comprising 569 Norwegian and 282 Finnish athletes recruited from different sports ( Table 1) .
The Finnish athletes were younger than the Norwegians before inclusion and had fewer ACL injuries. The Finnish cohort originally included men and women, but only data from the female participants were included in this study. From the original Norwegian cohort, athletes with insufficient data on previous ACL injury were excluded (n = 37). Otherwise, all athletes whose genotype could be defined were included. Genotype and history of ACL injury were available from 851 athletes. Overall, 119 participants (14.0%) had at least 1 ACL injury, while 58 (7.3%) of 790 participants with no prior ACL injury had at least 1 during the follow-up period.
The allelic distribution of the 6 SNVs, localized in the COL1A1, COL3A1, COL5A1, and COL12A1 genes, followed the Hardy-Weinberg equilibrium in the total sample as well as in the Norwegian and Finnish cohorts. Table 2 presents the genotype and minor allele frequencies of all sequence variants in the total sample and in the Norwegian and Finnish subgroups. The distribution pattern was almost similar between the 2 groups, with the exception of the SNV in the COL12A1 gene, where the genotypes and the C allele differed between the Norwegian and Finnish cohorts (P \ .001). In addition, the A allele of rs1800012 in the COL1A1 gene was more abundant in the Norwegian cohort than in the Finnish study (0.18 vs 0.14; P \ .03). The results of the genetic association analyses are presented in Table 3 . The genotype and minor allele frequencies of all the SNVs in athletes with no ACL injuries (n = 732) were first compared with the frequencies in athletes with ACL injury before or after inclusion (n = 119). There were no significant associations, neither in the unadjusted analyses nor when adjusting for cohort and sport. We then compared athletes with no history of ACL injury (n = 790) with athletes with ACL injury after inclusion in the study (n = 58). There were no associations in the unadjusted analyses. When adjusting for country and sport, the genotype frequencies of rs13946 in the COL5A1 gene showed a significant association (P = .019). No athletes who suffered an ACL injury in the follow-up period had the C/C genotype.
The results of the adjusted analyses are presented in Table 4 .
Separate analysis of the 2 SNVs with different distributions between the national cohorts (rs1800012 and rs970547) did not reveal any associations with ACL injury risk.
In a comparison of athletes with an ACL injury before inclusion (n = 61) and those with no history of ACL injury (n = 790), the risk ratio for suffering a new ACL injury during follow-up was 2.5 (95% CI, 1.4-4.6; P \ .01).
DISCUSSION
This first prospective cohort study on the association between collagen gene variants and risk of ACL injury does not support previous findings from case-control studies that SNVs localized in genes coding for collagen proteins represent risk factors for ACL injury. Several factors could have influenced this. First, our study was designed as a cohort study with better control of confounding factors and less risk of bias than previously published case-control studies. Second, the present study was performed in Norwegian and Finnish athlete populations, which may differ genetically from South African and Polish athlete populations where most previous ACL association studies were carried out. Third, the participants in this study were all female elite athletes, whereas several previous studies included men only. [27] [28] [29] Last, differences in recruitment strategy among the published studies may have contributed to differences in the study populations. The participating athletes in the present study were all from high-risk team sports, in contrast to previous studies that recruited convenience samples of recreational athletes and participants from the general population. Even though contact injuries were excluded in the analyses, there is a possibility that the energy causing the injuries in the current study was greater than that in comparable studies. If so, intrinsic factors could play a smaller role in the risk profile. Several studies suggested that the homozygous A/A genotype of the rs1800012 SNV in the COL1A1 gene is protective against ACL injury as well as other soft tissue injuries. 2, 16, 23 This could not be verified in the present study. Of 119 participants with ACL injury, 2 (1.7 %) were carriers of the A/A genotype. However, the carrier frequency was only 2.5% among the controls in our study, as compared with 4.6% in the study by Posthumus et al. 23 In a Polish study, the distribution of this genotype was 2.5% in the control group, and no protective effect of this genotype was found.
3 This is similar to our findings. In the same study, Ficek and coworkers 3 reported no association between the rs1107946 variant of the COL1A1 gene and ACL injury, which is in line with our results. Two studies from the Polish population identified the A/A genotype of the rs1800255 SNV in the COL3A1 gene as a risk factor for ACL injury, 21, 29 whereas no association was found in the South African population. 21 The latter finding is in line with our results.
An association was earlier reported between the C/C genotype of the rs12722 variant in the COL5A1 gene and reduced risk for ACL injuries among female South Africans. 25 In that study, the authors found a substantial difference in the C/C genotype between females with ACL rupture (27.4%) and without (5.6%). Thus, the results were highly significant, even though not more than 122 athletes were included in the study. The results were not confirmed in a study on male Polish skiers 28 or in our study. Neither in the Polish nor the South African population was an association found between the rs13946 of COL5A1 and ACL injury. 25, 28 In our study, we found a protective effect of the C/C genotype in the adjusted analyses, not the unadjusted. It is noteworthy that the Fisher exact test used in the unadjusted analysis of this genotype resulted in a P value of .06, which is near the level of significance. In the adjusted analyses, we had to use logistic regression, which resulted in a P value below the level. If we were to use logistic regression in the unadjusted analysis, the result would have been statistically significant as well (P = .015). All in all, this indicates that it might be a protective effect of the C/C genotype, as no ACL injury in the follow-up period was registered for athletes with this genotype (Table 3) . However, the possible protective effect is probably not strong, as 4 ACL injuries among athletes with this genotype were registered before start of the prospective registration.
The most common genotype of the rs970547 variant in the COL12A1 gene is the homozygous T/T. In 1 study, this genotype was overrepresented in female athletes with ACL rupture. 24 However, in the same study, this was not the case for male participants. In contrast, an Indian study that contained mainly male patients found that the C/T and C/C alleles were underrepresented in patients with ACL tear. 13 However, an association was not found in a study of Polish footballers 4 or in the present study. In recent years, opportunities to screen the entire genome for SNVs have emerged. A recent case-control study used a genome-wide approach to study the association between SNVs and ACL injury. 17 The study included 598 patients with ACL ruptures and 98,744 controls. After variance analysis covering all SNVs registered, no variant was significantly associated with ACL injury at the genome level. Furthermore, none of the SNVs previously reported to be associated with ACL injury were significantly associated in this study.
One limitation of our study is the limited number of ACL cases. However, the absolute differences in genotype distribution and minor allele frequency between the athletes with and without ACL injury are small and unlikely to be clinically significant. The follow-up period is also limited. However, the incidence of ACL injuries in the cohort is much higher than in the general population. Although athletes are likely to enjoy a relatively active lifestyle even after the end of their elite careers, their risk of acquiring an ACL injury then is probably similar to the general population.
In conclusion, our study does not support a role of the 6 selected SNVs in genes encoding for collagen proteins as risk factors for ACL injury. Although a genetic predisposition may exist, the importance of this-and thus the clinical significance-is unclear. Theoretically, measures to prevent ACL injuries could be targeted to individuals with a specific genetic makeup, but currently there is no evidence supporting such an approach. 
